Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
epilepsy
Biotech
Praxis' epilepsy drug hits in phase 2, sparking stock rise
Praxis linked the high dose of PRAX-628 to a 100% complete response rate to clear the path for a larger study in the second half of the year.
Nick Paul Taylor
Mar 26, 2024 10:24am
Stoke's shares up 90% as epilepsy drug cuts convulsive seizures
Mar 26, 2024 9:09am
Neurona knocks out $120M raise a year after layoffs
Feb 8, 2024 8:00am
FDA approves Medtronic’s rechargeable deep brain stimulator
Jan 10, 2024 10:20am
Longboard’s shares triple as epilepsy med halves seizure rates
Jan 2, 2024 10:49am
Gene therapy curbs hard-to-treat form of epilepsy in mice
Dec 15, 2023 6:00am